Oscar Clinical Guideline: Somatostatin Analogs - Medical Benefit Preferred Physician-Administered Drug Exceptions Criteria (CG078, Ver. 4)

Somatostatin Analogs - Medical Benefit Preferred Physician-Administered Drug Exceptions Criteria

Disclaimer

Clinical guidelines are developed and adopted to establish evidence-based clinical criteria for utilization management decisions. Clinical guidelines are applicable according to policy and plan type. The Plan may delegate utilization management decisions of certain services to third parties who may develop and adopt their own clinical criteria.

Coverage of services is subject to the terms, conditions, and limitations of a member's policy, as well as applicable state and federal law. Clinical guidelines are also subject to in-force criteria such as the Centers for Medicare & Medicaid Services (CMS) national coverage determination (NCD) or local coverage determination (LCD) for Medicare Advantage plans. Please refer to the member's policy documents (e.g., Certificate/Evidence of Coverage, Schedule of Benefits, Plan Formulary) or contact the Plan to confirm coverage.

Summary

The Plan has a Medical Preferred Drug List to encourage use of cost-effective and clinically appropriate physician-administered specialty drugs. Table 1 lists the preferred and non-preferred Somatostatin and analogs:

Table 1: Somatostatin Analogs, Medical Preferred Drug List

Preferred Product[*]	*Non-Preferred Products*[†/*]
❖ Somatuline Depot (lanreotide) [J1930]	❖ lanreotide (Cipla) [J1932] ❖ Sandostatin (octreotide, non-depot) [J2354] ❖ Sandostatin LAR Depot (octreotide acetate) [J2353] ❖ Signifor LAR (pasireotide) [J2502]

	❖ Somavert (pegvisomant) [J3590]

[N]subject to Plan's Preferred Physician-Administered Drug(s) Exceptions Criteria.

[*]*Other drug-specific or class-specific clinical guidelines may also be applicable.*

- *Products considered Formulary or Preferred for the Plan may still require a clinical prior authorization review.*
- *The Plan may review all requests made under the Medical or Pharmacy benefit against specific prior authorization criteria, as applicable and at its discretion.*

This policy outlines the Plan's preferred products and exception criteria for non-preferred products through prior authorization. The coverage review process will determine if a clinical exception can be made.

- The program applies to all members requesting treatment with a non-preferred product (see Table 1).
- Preferred drugs are selected based on clinical effectiveness, safety, FDA approval, and treatment guidelines. In most cases, preferred medications must be tried first as long as they are considered safe and effective by the provider.
- Requests for non-preferred medications may require meeting Medical Benefit Preferred Drug Exceptions Criteria. Approval may be given if the member has tried and failed, or cannot use the Plan's preferred drug(s). Exceptions may include, but are not limited to the following:
    1. The member has a documented trial and failure, inadequate response, intolerance, or contraindication to ALL preferred drug(s), as applicable; ***or***
    2. The member has a risk factor(s) for poor response to the preferred drug(s); ***or***
    3. The member is not a candidate for the preferred drug(s) based on the member's condition(s), individual needs, treatment history, or accepted standards of medical practice.

For more information or to request an exception, please contact the Plan.

Authorization Requirements and Submission Process

Indication Type	Review Entity	Submission Methods	Contact Information
Oncology	EviCore	Provider Portal	www.evicore.com
		Phone	855-252-1118
		Fax	800-540-2406

Non-Oncology	The Plan (Oscar)	Online Portal	Use the authorization tool at provider.hioscar.com
		Phone	855-672-2755
		Fax	Submit form from www.hioscar.com/forms
Need to check requirements or status? Visit provider.hioscar.com or call 1-855-672-2755			

Definitions

"**Compendia**" are summaries of drug information and medical evidence to support decision-making about the appropriate use of drugs and medical procedures. Examples include, but are not limited to:

1. American Hospital Formulary Service Drug Information
2. Elsevier Clinical Pharmacology
3. National Comprehensive Cancer Network Drugs and Biologics Compendium
4. Thomson Micromedex DrugDex
5. United States Pharmacopeia-National Formulary (USP-NF)

"**Contraindication**" refers to a pre-existing condition or factor that precludes use of a drug due to risk of harm.

"**Intolerance**" refers to the inability to tolerate or endure something, often due to experiencing subjectively difficult or harmful side effects, reactions, or hypersensitivities when using a medication or treatment that negatively impacts quality of life, ability to adhere, or overall health. Documentation is expected to detail the specific intolerable effects and their impact on treatment.

"**Documentation**" refers to written information, including but not limited to:

1. Up-to-date chart notes, relevant test results, and/or relevant imaging reports to support diagnoses;
2. Prescription claims records, and/or prescription receipts to support prior trials of alternatives.

"**Experimental or Investigational**" are procedures, drugs, or devices that haven't been proven effective or which haven't been approved by the appropriate regulatory bodies.

"**FDA**" refers to the Federal Food and Drug Administration.

"**Medical Benefit Preferred Drug Exceptions Criteria**" are Plan requirements that must be met for a non-preferred drug to be approved for coverage, such as trial and failure of preferred drugs first.

State Law Conflicts

For any provision of this policy that directly conflicts with or is prohibited by state law, the provisions of the state law will apply instead of the provisions of this policy. This means that in instances where state regulations diverge from or directly oppose the Plan's Preferred Physician-Administered Drug(s) Exceptions Criteria or requirements, the policy's criteria will not apply.

Exception Criteria for Non-Preferred Products

A. For Non-Preferred Immediate-Release/Short-Acting Formulations

➢ *Applies to octreotide (non-depot) [J2354]*

Coverage for a **Non-Preferred Immediate-Release/Short-Acting Product** will be provided when the member meets **ANY** of the following criteria:

1. Documentation supports medical necessity of immediate-release formulation due to:
    a. Need for acute symptom management***; or***
    b. Initial therapy or dose titration before transitioning to long-acting formulation***; or***
    c. Clinical scenario requiring rapid dose adjustments***; or***
    d. Medical necessity for short-acting formulation based on the member's condition(s) and treatment requirements***; OR***
2. Documentation shows inadequate response or treatment failure with the preferred product Somatuline Depot (lanreotide), unless:
    a. There is a drug shortage or unavailability of the preferred product ***; or***
    b. The member experienced an intolerable adverse event to the preferred product***; or***
    c. Preferred product is contraindicated for the member***; or***
    d. Preferred product lacks FDA approval, evidence-based guideline support, or is not clinically appropriate for the member's diagnosis***; OR***
3. The request is for cancer treatment in a state prohibiting prerequisite trials per regulations**.**

B. For Non-Preferred Long-Acting Depot Formulations

➢ *Applies to long-acting products:*

- *lanreotide (Cipla) [J1932]*

- *Sandostatin LAR Depot (octreotide acetate) [J2353]*
- *Signifor LAR (pasireotide) [J2502]*
-
- *Somavert (pegvisomant) [J3590]*

Coverage for a **Non-Preferred Long-Acting Depot Formulations** will be provided when the member meets **BOTH** of the following criteria:

1. Documentation shows inadequate response or treatment failure with the preferred product Somatuline Depot (lanreotide), unless:
    a. There is a drug shortage or unavailability of the preferred product ***; or***
    b. The member experienced an intolerable adverse event to the preferred product***; or***
    c. Preferred product is contraindicated for the member***; or***
    d. Preferred product lacks FDA approval, evidence-based guideline support, or is not clinically appropriate for the member's diagnosis (e.g., Cushing's disease requiring Signifor LAR)***; or***
    e. The request is for cancer treatment in a state prohibiting prerequisite trials per regulations***; AND***
2. Clinical documentation is provided to support the exception request. Examples of supporting documentation include:
    a. Specific details of inadequate response/treatment failure***; and/or***
    b. Nature and severity of adverse events***; and/or***
    c. Specific contraindications***; and/or***
    d. Clinical rationale for diagnosis-specific product needs.

C. Additional Brand/Generic Requirements

➢ *Applies to brand Sandostatin (non-depot) [J2354] and brand Sandostatin LAR Depot [J2353]*

In addition to meeting the applicable criteria above, for brand product requests, documentation must show trial and failure of, or contraindication to, the corresponding generic product, unless:

1. The member experienced an intolerable adverse event to the generic product***; OR***
2. The member has a documented contraindication specific to an inactive ingredient in the generic product***; OR***
3. Provider submits clinical documentation supporting medical necessity of Brand over generic product.

If the above prior authorization criteria are met, the requested product will be authorized for up to 12-months.

- **For drug shortage/unavailability:**

- **Initial approval - 3 months;**
- **May be extended based on continued documentation of shortage/unavailability.**

  Note: If the shortage/unavailability resolves before the authorization period ends, the Plan may require transition to the preferred product at the next authorization period.

Experimental or Investigational / Not Medically Necessary

The Plan does not cover non-preferred products when used for experimental, investigational, or medically unnecessary indications. Use of non-preferred products is considered experimental, investigational, or not medically necessary if the indication is outside FDA-approved labeling or not supported by current medical evidence and standards of care. The Plan does not cover non-preferred products for the following non-approved indications (not all-inclusive):

1. Uses not considered clinically appropriate based on indication, including age, dosing (dosage, frequency, duration of therapy, and site of administration), and contraindication.
    a. Non-FDA approved indications or off label use without sufficient evidence supporting safety and efficacy.
    b. Doses exceeding the FDA-approved label or clinical practice guidelines without sufficient evidence supporting safety and efficacy.
2. Uses not required for treatment or management of the member's medical condition.
3. Uses not aligned with generally accepted medical practice.
4. Uses primarily for the convenience of the member, family, or provider.

Applicable Billing Codes (HCPCS/CPT Codes)

CPT/HCPCS Codes considered medically necessary if criteria are met:	
Code	*Description*
C9399 (NOC)	Unclassified drugs or biologicals
J1930	Injection, lanreotide, 1 mg
J1932	Injection, lanreotide, (Cipla), 1 mg
J2353	Injection, octreotide, depot form for intramuscular injection, 1 mg
J2354	Injection, octreotide, non-depot form for subcutaneous or intravenous injection, 25 mcg

J2502	Injection, pasireotide long acting, 1 mg
J3490 (NOC)	Unclassified drugs
J3590 (NOC)	Unclassified biologics

References

1. Somatuline Depot (lanreotide) [prescribing information]. Cambridge, MA: Ipsen Biopharmaceuticals, Inc; February 2023.
2. Somatuline Depot (lanreotide) [prescribing information]. Cambridge, MA: Ipsen Biopharmaceuticals, Inc; July 2024.
3. Somavert (pegvisomant) [prescribing information]. New York, NY: Pharmacia & Upjohn Co; July 2023.
4. Sandostatin LAR Depot (octreotide injection suspension) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; March 2021.
5. Signifor (pasireotide) [prescribing information]. Bridgewater, NJ: Recordati Rare Diseases Inc; July 2024.
6. Signifor LAR (pasireotide) [prescribing information]. Bridgewater, NJ: Recordati Rare Diseases Inc; July 2024.
7. Signifor LAR (pasireotide) [prescribing information]. Lebanon, NJ: Recordati Rare Diseases Inc; June 2020.
8. Somavert (pegvisomant) [prescribing information]. New York, NY: Pharmacia & Upjohn Co; July 2023.

Clinical Guideline Revision / History Information

Original Date: 12/14/2023 Reviewed/Revised: 09/18/2024, 12/02/2024, 3/1/2025